watch
Shire PLC

Shire PLC

Sector: Pharmaceutical Preparations Region: PA, United States


: | Nasdaq: SHPG


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

The Path to US$10 Billion in Product Sales by 2020

Shire PLC video

The Path to US$10 Billion in Product Sales by 2020

Shire PLC video

Jefferies 2014 Global Healthcare Conference

Executives

Flemming Ornskov, MD, Chief Executive Officer
Flemming assumed the position of Chief Executive Officer on April 30, 2013 and has been a member of the Board since January 2, 2013. He is also a member of the Company’s Executive Committee.

Flemming brings to his position his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the position of Non-Executive Chairman of Evotec AG, and of Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer. Prior to this, from 2008 to 2010, Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc.. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Flemming had roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. He received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.
Tatjana May, General Counsel
Tatjana has been with Shire since May 2001. She is Shire's General Counsel and a member of Shire’s Executive Committee.

Ms May was previously Assistant General Counsel at the corporate headquarters of AstraZeneca plc and prior to that she worked at the law firm Slaughter and May.
James Bowling, Interim Chief Financial Officer
James joined Shire in 2005 and has been Shire's Group Financial Controller since 2008, leading Shire's Financial Reporting, Financial Planning & Analysis, and Treasury & Insurance teams. He currently holds the position of Interim Chief Financial Officer. He is also a member of Shire's Executive Committee.

Prior to joining Shire, James worked for Ford Motor Company in various finance roles. He is a Chartered Accountant having qualified with Touche Ross & Co.
Phil Vickers, Head of Research and Development
Phil has been with Shire since 2010. He led Research and Development within the Rare Diseases Business Unit and is now Shire’s Head of Research and Development. He is also a member of Shire’s Executive Committee.

Phil was previously Chief Scientific Officer and President at Resolvyx Pharmaceuticals, Inc., prior to which he worked for Boehringer Ingelheim Pharmaceuticals, Inc.. He also held positions at Pfizer, Inc. and Merck & Co., Inc..
Ginger Gregory, Chief Human Resources Officer
Ginger joined Shire in 2014 and is Shire’s Chief Human Resources Officer. She is also a member of Shire’s Executive Committee.

Ginger was previously Head of Human Resources at Dunkin’ Brands Group, Inc. prior to which she held roles at Bristol-Myers Squibb Company, Novo Nordisk A/S and Novartis AG.
Mark Enyedy, Head of Corporate Development
Mark has been with Shire since 2013. He initially led the Internal Medicine Business Unit and is now Shire’s Head of Corporate Development leading the Business Development, Planning and Program Management, and Strategy functions. He is also a member of Shire’s Executive Committee.

Prior to joining Shire Mark was Chief Executive Officer at Proteostasis Therapeutics, Inc.. He also held positions with Genzyme Corporation and practiced law at the firm Palmer & Dodge.

News & Analysis